Harvard expert on inflammation's role in obesity receives Columbia's 2010 Naomi Berrie Award

November 19, 2010

NEW YORK (Nov. 20, 2010) - Columbia University Medical Center will present the 2010 Naomi Berrie Award to a Harvard researcher who has made important advances in understanding the molecular basis for links between obesity, diabetes and heart disease. A promising young investigator at Columbia will also be recognized for her novel investigations regarding the basis for disordered lipid metabolism in diabetes.The awards ceremony will take place at the 12th Annual Frontiers in Diabetes Research Conference on "The Cardiovascular Consequences of Diabetes" being held today, Nov. 20, 2010, from 8:45 a.m. to 4:25 p.m. in the Russ Berrie Medical Science Pavilion, 1150 St. Nicholas Ave., New York, New York.

"Gökhan Hotamisligil's group studies have demonstrated that inflammation plays an important role in obesity, insulin resistance, and type 2 diabetes," said Rudolph Leibel, M.D., the co-director of the Naomi Berrie Diabetes Center, and chairman of the selection committee. "This work has led to novel ideas for the treatment of these disorders and their consequences."

Established by the Russell Berrie Foundation in 2000, the Naomi Berrie Award for Outstanding Achievement in Diabetes Research was designed to promote and reward outstanding achievement in the field, while simultaneously helping to promote important scientific collaborations across institutions and furthering the careers of especially promising young diabetes investigators. Each year, the recipient - a senior scientist outside Columbia who has made major contributions to diabetes research - is given $100,000 to support a two-year research fellowship for a student or research fellow in his or her laboratory. The second $100,000 award supports a research fellow at Columbia.

Dr. Hotamisligil Focuses on Immune Response and Underlying Mechanisms of Obesity

Recent years have witnessed a significant revision of the traditional view that fat cells simply store excess energy. Studies by Dr. Hotamisligil and his associates, as well as many others, have demonstrated that adipose tissue produces and regulates many metabolic and hormonal signals, generating profound effects on a body's endocrine equilibrium and in the development of diabetes.

Dr. Hotamisligil's research has played a preeminent role in the emergence of the concept that chronic inflammation is central to obesity and associated metabolic disorders, especially insulin resistance and type 2 diabetes. He developed one of the models designed to definitively link inflammation, immune response and insulin action when he discovered that JNK (Jun N-terminal kinase), a protein that influences DNA transcription and other cellular processes, is implicated in the control of expression of many genes involved in immune response On a cellular level, he has also identified the endoplasmic reticulum as a locus integrating nutrient and stress responses and its dysfunction as an important mechanism underlying obesity and type 2 diabetes.

Dr. Hotamisligil made early observations regarding cytokine production in adipose tissue, and has used these insights to understand the mechanisms that connect cytokine action to defective insulin signaling. Recently, his group identified an important connection between nutrients, JNK activity and endoplasmic reticulum function stress through a pathogen-sensing molecule. He has promoted the concept of the existence of "metabolic inflammasomes" that integrate metabolic processes with immune response and insulin signaling. These concepts link organelle function to metabolic homeostasis and suggest critical mechanisms involved in metabolic functions of endoplasmic reticulum and its failure in obesity.

Dr. Hotamisligil is the 2010 recipient of the Turkish Government Ministry's Health & Medical Excellence Award. In 2009, he was elected a Fellow of American Association for the Advancement of Science (AAAS). He obtained his Ph.D. in biological chemistry and molecular pharmacology from Harvard Medical School in 1995 and his M.D. from Ankara University Medical School in Ankara, Turkey in 1986. He is currently an advisory member of the Juvenile Diabetes Research Foundation (JDRF) Research Portfolio.

Naomi Berrie Fellow in Diabetes Research Awardee Focuses on Metabolic Pathways of Diabetes

The award to a the junior investigator goes to Rebecca A. Haeusler, Ph.D., a post-doctoral research scientist in the lab of Domenico Accili, M.D., director of the Columbia University Diabetes and Endocrinology Research Center at the Naomi Berrie Diabetes Center. Dr. Haeusler was cited for her work in understanding the roles of a certain transcription factor, FOXO1, in the disordered lipid metabolism and cardiovascular disease in diabetes.

Through her work she has found that FOXO1 protects against excessive hepatic lipid production in the context of hyperglycemia, and that its inhibition - a consequence of intensive insulin treatment used in diabetes - may paradoxically exacerbate some of the lipid abnormalities of diabetes. These insights have immediate implications for the clinical management of diabetes.

Dr. Haeusler hopes to extend these insights into the common abnormalities of lipid metabolism that are observed in patients with type 2 diabetes. "Understanding those processes will help us understand how atherosclerosis progresses over time, especially in the patients with type 2 diabetes," she added.

Dr. Haeusler earned her Ph.D. in Biological Chemistry from the University of Michigan in 2007 and her bachelor's degree in Biology from the Massachusetts Institute of Technology in 2000. She has received the Marija Dokmanovic-Chouinard Award for Excellence in Research, awarded by the Naomi Berrie Diabetes Center and the Columbia University Institute of Human Nutrition in October 2009; and was a Kern Aspen Lipid Conference Scholarship recipient, also in 2009. Her dissertation won the award for exceptional Ph.D. dissertation at the University of Michigan in 2007, out of 750 Ph.D. dissertations submitted.

Past recipients of the Naomi Berrie award for Outstanding Achievement in Diabetes Research are Graeme Bell, Ph.D., University of Chicago (2000); C. Ronald Kahn, M.D., Joslin Diabetes Center and Harvard Medical School, (2001); Clifton Bogardus III, M.D., National Institute of Diabetes & Digestive & Kidney Diseases (2002); George S. Eisenbarth, M.D., Ph.D., the University of Colorado Health Sciences Center (2003); Douglas Melton, Ph.D. of Harvard University (2004), Michael Brownlee of the Albert Einstein College of Medicine (2005); and Michael Schwartz, M.D., University of Washington (2006) and Gerald I. Shulman, M.D. Ph.D., of Yale University (2007) Bruce Spiegelman, Ph.D., Harvard University (2008) and Richard Nathan Bergman, Ph.D., of the University of Southern California.
-end-
The one-day Frontiers in Diabetes symposium on Nov. 20, 2010 is designed for scientist/investigators, students and clinicians with interests in diabetes and/or obesity and this year is focused on the role of inflammation and the cardiovascular consequences of diabetes. All interested individuals at Columbia are encouraged to attend. Pre-registration is advised: http://ColumbiaCME.org

Upon its official opening in October 1998, the Naomi Berrie Diabetes Center at Columbia University Medical Center established a new standard of care for the 1.6 million people with diabetes in the New York area--combining world-class diabetes research and education programs with unprecedented family-oriented patient care. Named for the mother of the late Russell Berrie, founder of RUSS™ Toys, the center is today recognized as the most comprehensive diabetes research and treatment center in the tri-state region, and has been designated as a national "Diabetes Center of Excellence" - one of only three in the state of New York. For more information, visit www.nbdiabetes.org.

Columbia University Medical Center provides international leadership in basic, pre-clinical and clinical research, in medical and health sciences education, and in patient care. The medical center trains future leaders and includes the dedicated work of many physicians, scientists, public health professionals, dentists, and nurses at the College of Physicians and Surgeons, the Mailman School of Public Health, the College of Dental Medicine, the School of Nursing, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. Established in 1767, Columbia's College of Physicians and Surgeons was the first institution in the country to grant the M.D. degree and is now among the most selective medical schools in the country. Columbia University Medical Center is home to the most comprehensive medical research enterprise in New York City and State and one of the largest in the United States. Columbia University Medical Center is affiliated with NewYork-Presbyterian Hospital, the nation's largest not-for-profit, non-sectarian hospital provider. For more information, please visit www.cumc.columbia.edu.

NewYork-Presbyterian Hospital, based in New York City, is the nation's largest not-for-profit, non-sectarian hospital, with 2,353 beds. The Hospital has nearly 2 million inpatient and outpatient visits in a year, including more than 220,000 visits to its emergency departments -- more than any other area hospital. NewYork-Presbyterian provides state-of-the-art inpatient, ambulatory and preventive care in all areas of medicine at five major centers: NewYork-Presbyterian Hospital/Weill Cornell Medical Center, NewYork-Presbyterian Hospital/Columbia University Medical Center, NewYork-Presbyterian/Morgan Stanley Children's Hospital, NewYork-Presbyterian/The Allen Hospital and NewYork-Presbyterian Hospital/Westchester Division. One of the most comprehensive health care institutions in the world, the Hospital is committed to excellence in patient care, research, education and community service. NewYork-Presbyterian is the #1 hospital in the New York metropolitan area and is consistently ranked among the best academic medical institutions in the nation, according to U.S. News & World Report. The Hospital has academic affiliations with two of the nation's leading medical colleges: Weill Cornell Medical College and Columbia University College of Physicians and Surgeons. For more information, visit www.nyp.org.

Columbia University Medical Center

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.